NEWS

We Work for Health's Executive Director Dan Leonard recently sat down with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum (NMQF), to discuss his organization's work to ensure fair access to life-saving research and emerging treatments as well as what needs to be done to preserve America's innovation leadership.   The discussion highlighted the public health and economic imperatives of maintaining U.S. competitiveness in biopharmaceutical research

November 26, 2025   (Washington, DC) We Work For Health Executive Director Dan Leonard issued the following statement in response to the administration’s announcement on the Maximum Fair Prices (MFP) for IPAY 2027 selected drugs:   “We Work For Health has been sounding the alarm about the dangers of government price controls since the passage of the Inflation Reduction Act (IRA). This latest announcement from the Administration is yet another troubling consequence of that pol

Members of the Senate Special Committee on Aging convened last week to hear from witnesses on restoring trust in American-made medicines.   The hearing  highlighted urgent concerns about America’s reliance on foreign nations, particularly China, for critical drug ingredients and finished medications.   Witnesses and lawmakers warned that this dependence is compromising patient safety, national security and supply-chain resilience.   As Senator Scott (R-FL) said in his opening

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security.   According to a recent STAT article , while U.S. biotech stock is up 20% this year, China's is up a whopping 80%. At first glance, this could be dismissed as another short-term spike. Similar ones were observed between 2018 and 2021 when a flurry of Chinese drugmakers launched IPO

North Carolina’s life sciences industry is a hub of innovation that drives economic growth and advances health care.   Its research and biotech sectors employ more than 226,000 people  and contribute more than $80 billion  to the state’s economy. Through thousands of clinical trials involving millions of participants, the state plays a central role in finding discoveries that improve patient care nationwide.   That’s where strong intellectual property (IP) protections come in

The urgency for the U.S. to maintain its leadership in biotechnology – especially in competition with China – is growing. This issue came into sharp focus during recent discussions between lawmakers and industry experts at a Senate HELP Committee hearing .    “I recently spoke to a group of biotech leaders,” Sen. Bill Cassidy (R-LA) said. “They, in varying degrees, view China as a collaborator, a competitor and as a threat. When developers are looking outside our country for

As we wrap up IP Month, WWFH Executive Director Dan Leonard sat down for a conversation with David Kappos of the Council for Innovation Promotion. As former Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office and Vice President and Chief Intellectual Property Lawyer at IBM, Kappos is an expert in the innovation and intellectual property (IP) space.  Throughout the conversation, Kappos underscores the fundamental importance of strong IP protections

We Work For Health Executive Director Dan Leonard recently sent a letter to the Food and Drug Administration (FDA) commending its commitment to expanding domestic drug research and manufacturing capabilities. He also urged the agency to encourage continued progress in fortifying the nation’s pharmaceutical supply chain. For more on how U.S. investments are driving innovation, explore WWFH's Biopharma Investment Watch .